Video interview with BioViva’s Liz Parrish

BioViva and Integrated Health Systems: How many patients in trials? Where are they located? What pipeline stage?

As we’ve covered in the past, BioViva’s Liz Parrish has ambitions to progress the Longevity field, and as with many early-stage companies, things move fast as financial, regulatory and market dynamics change.

Longevity.Technology: We weren’t completely clear on BioViva’s strategy so we thought a video interview would be a great way to share the insights; so from telomere testing kits for pets (as a roadmap to human therapies) through to going into clinical trials with human data:

As Liz told us earlier this year: “… if it’s agreed between the medical doctor and the patient to take an experimental therapeutic they can do that. And that should be the right anywhere in the world – everyone should have the agency and autonomy to do that. Unfortunately, they don’t.”

 

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Reproductive Longevity – taking the geroscience approach

Applying geroscience interventions to fertility pathways can promote reproductive Longevity. Dr Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge...

Targeting senescent cells to extend lifespan

Although our understanding of the mechanisms underlying aging is limited, recent findings from animal studies indicate that targeting cellular senescence in vivo may prevent...

At-home wellness biomarker test to deliver instant results

ZiO Health prepares to launch crowdfunding campaign for subscription-based urine test that measures multiple health biomarkers. Biomedical start-up ZiO Health is on a mission to...

Inflammaging biotech acquired by Roche for €380m

One of the largest deals in Irish biotech history sees Roche gain rights to full Inflazome portfolio. The Swiss company Roche has bought Dublin-based biotech...